Edition:
United States

Curis Inc (CRIS.O)

CRIS.O on Consolidated Issue listed on NASDAQ Global Market

1.70USD
25 May 2017
Change (% chg)

$-0.01 (-0.58%)
Prev Close
$1.71
Open
$1.74
Day's High
$1.74
Day's Low
$1.69
Volume
61,446
Avg. Vol
527,759
52-wk High
$3.72
52-wk Low
$1.47

CRIS.O

Chart for CRIS.O

About

Curis, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company's drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of... (more)

Overall

Beta: 2.00
Market Cap(Mil.): $245.85
Shares Outstanding(Mil.): 143.77
Dividend: --
Yield (%): --

Financials

  CRIS.O Industry Sector
P/E (TTM): -- 138.86 17.42
EPS (TTM): -0.49 -- --
ROI: -97.99 2.17 -5.45
ROE: -172.34 0.04 -4.73

BRIEF-Curis Q1 loss per share $0.11

* Q1 earnings per share view $-0.09 -- Thomson Reuters I/B/E/S

May 04 2017

BRIEF-Curis Q4 loss per share $0.08

* Curis reports fourth quarter and year-end 2016 financial results

Mar 09 2017

BRIEF-Curis Inc exercised its option to extend exclusivity period with Aurigene

* Curis Inc - exercised its option to extend exclusivity period with Aurigene Source text for Eikon: Further company coverage:

Jan 09 2017

BRIEF-Curis says announces full approval of Roche's Erivedge in European Union

* Says announces full approval of Roche's Erivedge in European Union

Nov 28 2016

More From Around the Web

Earnings vs. Estimates